Skip to content
value.today

Augmedix, Inc.

Total raised
$12 M
1 round on record
Latest round
$12 M
Apr 2023
First round on record
Apr 2023
Today
Private
No later event on record

Funding rounds

1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Augmedix, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Apr 2023$12 MNo. 1$10 to $50 million

Augmedix, Inc.: Raise no. 1, Apr 2023

Investors in this round

2 investors had bought by the notice of May 3, 2023: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Emmanuel Krakaris · Executive Officer, Director
  • Ian A. S. Shakil · Director
  • Jason A. S. Krikorian · Director
  • Joseph A. S. Marks · Director
  • Laurie A. S. McGraw · Director
  • Margie A. S. Traylor · Director
  • Robert J. Faulkner · Director
  • Roderick J. O'Reilly · Director
  • William J. Febbo · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emmanuel Krakaris, Chief Executive Officer. Source: SEC Form D, newest notice filed May 3, 2023. Read the notice at the SEC.

equity, optionsSEC
Oct 2020$30 MIssued in a merger or acquisition$10 to $50 million

Augmedix, Inc.: Private sale, Oct 2020

Investors in this round

61 investors had bought by the notice of Oct 19, 2020: 61 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$30 M of $30 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Emmanuel Krakaris · Executive Officer, Director
  • Ian Shakil · Executive Officer, Director
  • Jonathan M. Hawkins · Executive Officer
  • Sandra Breber · Executive Officer
  • Gerard van Hamel Platerink · Director
  • Jason Krikorian · Director
  • Jennifer M. Carter · Director
  • Joseph Marks · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Emmanuel Krakaris, President, CEO and Secretary. Source: SEC Form D and 1 amendment, newest notice filed Oct 19, 2020. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Augmedix, Inc. chose not to state its revenue in its newest notice of a funding round (May 2023).

    SEC Form D · May 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · May 2023

That is all the official record says: Augmedix, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Augmedix, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 2 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Augmedix, Inc.
NameRoleNamed in
Emmanuel KrakarisExecutive officerMay 2023
Ian ShakilExecutive officerOct 2020
Jonathan M. HawkinsExecutive officerOct 2020
Paul GinocchioExecutive officerOct 2020
Sandra BreberExecutive officerOct 2020
Emmanuel KrakarisDirectorMay 2023
Ian A. S. ShakilDirectorMay 2023
Jason A. S. KrikorianDirectorMay 2023
Joseph A. S. MarksDirectorMay 2023
Laurie A. S. McGrawDirectorMay 2023
Margie A. S. TraylorDirectorMay 2023
Robert J. FaulknerDirectorMay 2023
Roderick J. O'ReillyDirectorMay 2023
William J. FebboDirectorMay 2023
Gerard van Hamel PlaterinkDirectorOct 2020
Ian ShakilDirectorOct 2020
Jason KrikorianDirectorOct 2020
Jennifer M. CarterDirectorOct 2020
Joseph MarksDirectorOct 2020